WallStreetZenWallStreetZen

NASDAQ: PTGX
Protagonist Therapeutics Inc Stock Forecast, Predictions & Price Target

Analyst price target for PTGX

Based on 5 analysts offering 12 month price targets for Protagonist Therapeutics Inc.
Min Forecast
$34.00+66.99%
Avg Forecast
$37.00+81.73%
Max Forecast
$41.00+101.38%

Should I buy or sell PTGX stock?

Based on 5 analysts offering ratings for Protagonist Therapeutics Inc.
Strong Buy
Strong Buy
3 analysts 60%
Buy
2 analysts 40%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their PTGX stock forecasts and price targets.

PTGX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2023-11-03
lockedlocked$00.00+00.00%2023-10-10
lockedlocked$00.00+00.00%2023-09-25
lockedlocked$00.00+00.00%2023-07-03
lockedlocked$00.00+00.00%2023-07-03

1 of 1

Forecast return on equity

Is PTGX forecast to generate an efficient return?
Company
N/A
Industry
-0.69%
Market
30.36%

Forecast return on assets

Is PTGX forecast to generate an efficient return on assets?
Company
N/A
Industry
-0.29%

PTGX revenue forecast

What is PTGX's revenue in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
$55.0M
Avg 2 year Forecast
$25.0M
Avg 3 year Forecast
$70.3M

PTGX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
PTGX$20.36$37.00+81.73%Strong Buy
VRNA$14.62$32.25+120.59%Strong Buy
RCUS$15.77$44.38+181.39%Strong Buy
INBX$24.97$27.00+8.13%Buy
BCRX$5.69$13.83+143.11%Strong Buy

Protagonist Therapeutics Stock Forecast FAQ

Is Protagonist Therapeutics Stock a good buy in 2023, according to Wall Street analysts?

The consensus among 5 Wall Street analysts covering (NASDAQ: PTGX) stock is to Strong Buy PTGX stock.

Out of 5 analysts, 3 (60%) are recommending PTGX as a Strong Buy, 2 (40%) are recommending PTGX as a Buy, 0 (0%) are recommending PTGX as a Hold, 0 (0%) are recommending PTGX as a Sell, and 0 (0%) are recommending PTGX as a Strong Sell.

If you're new to stock investing, here's how to buy Protagonist Therapeutics stock.

What is PTGX's revenue growth forecast for 2023-2025?

(NASDAQ: PTGX) Protagonist Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.66%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 7.66%.

Protagonist Therapeutics's revenue in 2023 is $0.On average, 2 Wall Street analysts forecast PTGX's revenue for 2023 to be $3,172,296,710, with the lowest PTGX revenue forecast at $2,883,906,100, and the highest PTGX revenue forecast at $3,460,687,320. On average, 2 Wall Street analysts forecast PTGX's revenue for 2024 to be $1,441,953,050, with the lowest PTGX revenue forecast at $865,171,830, and the highest PTGX revenue forecast at $2,018,734,270.

In 2025, PTGX is forecast to generate $4,056,675,355 in revenue, with the lowest revenue forecast at $346,068,732 and the highest revenue forecast at $7,498,155,860.

What is PTGX's forecast return on assets (ROA) for 2023-2026?

(NASDAQ: PTGX) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of -0.29%.

What is PTGX's Price Target?

According to 5 Wall Street analysts that have issued a 1 year PTGX price target, the average PTGX price target is $37.00, with the highest PTGX stock price forecast at $41.00 and the lowest PTGX stock price forecast at $34.00.

On average, Wall Street analysts predict that Protagonist Therapeutics's share price could reach $37.00 by Nov 3, 2024. The average Protagonist Therapeutics stock price prediction forecasts a potential upside of 81.73% from the current PTGX share price of $20.36.

What is PTGX's forecast return on equity (ROE) for 2023-2026?

(NASDAQ: PTGX) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.